PTC Therapeutics Stock News

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director of Investor Relations Matthew Klein - Chief Execu

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wal

PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.

PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metri

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $0.29. This compares to loss of $2.35 per share a year ago.

SOUTH PLAINFIELD, N.J. , Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44t

The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the co

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Execu

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall St

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.

The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma.

PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monetize up to $1.5 billion of the royalty stream for t

SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 finan